Loading...

Sino Biopharmaceutical Limited

1177.HKHKSE
Healthcare
Biotechnology
HK$5.30
HK$0.13(2.51%)

Sino Biopharmaceutical Limited 1177.HK Peers

See (1177.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
1177.HKHK$5.30+2.51%94.8B48.18HK$0.11+10.37%
1801.HKHK$77.35-6.13%129.8B-1310.00-HK$0.06N/A
2269.HKHK$25.15+0.60%102.3B29.59HK$0.85N/A
9926.HKHK$92.50-2.48%82.9B-142.31-HK$0.65N/A
1530.HKHK$22.70+1.34%51.8B23.60HK$0.93+1.10%
3759.HKHK$15.94+2.31%43.2B13.86HK$1.15+1.48%
9995.HKHK$55.55-6.17%38B-18.64-HK$2.98N/A
6821.HKHK$74.40+4.06%32.8B24.16HK$3.08+1.62%
1877.HKHK$20.90-7.93%31.3B-15.00-HK$1.42N/A
1548.HKHK$14.50-3.07%31.3B-22.72-HK$0.64N/A
Showing 1 to 10 of 56 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

1177.HK vs 1801.HK Comparison

1177.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1177.HK stands at 94.8B. In comparison, 1801.HK has a market cap of 129.8B. Regarding current trading prices, 1177.HK is priced at HK$5.30, while 1801.HK trades at HK$77.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1177.HK currently has a P/E ratio of 48.18, whereas 1801.HK's P/E ratio is -1310.00. In terms of profitability, 1177.HK's ROE is +0.11%, compared to 1801.HK's ROE of -0.01%. Regarding short-term risk, 1177.HK is less volatile compared to 1801.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1177.HK.

Stock Price Comparison

Loading...

Frequently Asked Questions

;